ArticleOpen forum infectious diseases2018
Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.
Article in Open forum infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 107 citations in OpenAlex.
- Diagnostic utility of oropharyngeal swabs as an alternative to lower respiratory tract samples for PCR-based syndromic testing in patients with community-acquired pneumonia.Journal of clinical microbiology · 2023Trial
- Trial
- Observational
- Post-pandemic surge ofJournal of clinical microbiology · 2026Article
- Article
- Syndromic molecular testing in mechanically ventilated patients with severe pneumonia: a supportive diagnostic approach.Microbiology spectrum · 2026Article
- Case Report: Rare Community-Acquired Pneumonia with Concurrent Methicillin-ResistantInfection and drug resistance · 2026Article
- Combined nasopharyngeal and oropharyngeal sampling improves pathogen detection in community-acquired pneumonia.Frontiers in microbiology · 2026Article
- Xiaoxianxiong Decoction Attenuates LPS-Induced Pneumonia in Mice by Inhibiting Inflammatory Response Through Activation of SIRT1.FASEB bioAdvances · 2025Article
- Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.Medicina (Kaunas, Lithuania) · 2025Article
- A budget impact analysis of 15- or 20- valent pneumococcal conjugate vaccine use in all US adults aged 50-64 years old compared to those with high-risk conditions from US payer perspective.BMC public health · 2025Article
- Poor clinical outcomes in respiratory viral sepsis: a retrospective observational study.ERJ open research · 2025Article
- Alterations in the prevalence and serotypes of Streptococcus pneumoniae in elderly patients with community-acquired pneumonia: a meta-analysis and systematic review.Pneumonia (Nathan Qld.) · 2025Review
- C3 glomerulopathy associated with mycoplasma pneumoniae infection and positive IgA staining.BMC nephrology · 2025Article
- The incidence of radiologically verified community-acquired pneumonia requiring hospitalisation in adults living in southern Sweden, 2016-2018: a population-based study.BMC infectious diseases · 2025Article
- Description and characterization of pneumococcal community acquired pneumonia (CAP) among radiologically confirmed CAP in outpatients.NPJ primary care respiratory medicine · 2025Observational
- Incidence, healthcare-seeking behavior and barriers associated with seeking care for severe childhood pneumonia in rural Bangladesh: A prospective study.PLOS global public health · 2025Article
- Diagnosis and Therapy of Community-Acquired Pneumonia in the Emergency Department: A Retrospective Observational Study and Medical Audit.Journal of clinical medicine · 2024Article
- Aspirin reduces the mortality risk of patients with community-acquired pneumonia: a retrospective propensity-matched analysis of the MIMIC-IV database.Frontiers in pharmacology · 2024Article
- FOXA2 attenuates lipopolysaccharide‑induced pneumonia by inhibiting the inflammatory response, oxidative stress and apoptosis through blocking of p38/STAT3 signaling.Experimental and therapeutic medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe microbial etiology of community-acquired pneumonia (CAP) is often unclear in clinical practice, and previous studies have produced variable results. Population-based studies examining etiology and incidence are lacking. This study examined the incidence and etiology of CAP requiring hospitalization in a population-based cohort as well as risk factors and outcomes for specific etiologies.
methodsConsecutive admissions due to CAP in Reykjavik, Iceland were studied. Etiologic testing was performed with cultures, urine-antigen detection, and polymerase chain reaction analysis of airway samples. Outcomes were length of stay, intensive care unit admission, assisted ventilation, and mortality.
resultsThe inclusion rate was 95%. The incidence of CAP requiring hospitalization was 20.6 cases per 10000 adults/year. A potential pathogen was detected in 52% (164 of 310) of admissions and in 74% (43 of 58) with complete sample sets.
conclusionsPneumococci,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.